Actuate Therapeutics, Inc. Common stock Share Price & Technical Analysis
ACTU · $2.20 (-7.56%)
Healthcare / Biotechnology
$2.20
-7.56%
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of …
Price chart
Seasonality
May has 1 positive and 1 negative years (last 3 years shown)
-17% return in May, 31% avg return in past 3 year May month.
-83% return in 2026, -9% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -23% | -21% | -25% | 4% | -17% | – | – | – | – | – | – | – | -83% |
| 25 | 14% | -19% | -6% | 26% | 31% | -48% | 13% | 17% | -21% | 0% | 13% | -19% | 1% |
| 24 | – | – | – | – | – | – | – | -18% | -10% | 8% | 1% | -1% | -20% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$72.20M
P/E ratio
—
52W high
$11.99
52W low
$1.58
Volume
1,54,976
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Actuate Therapeutics, Inc. Common stock share price today?
- Actuate Therapeutics, Inc. Common stock (ACTU) last traded around $2.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ACTU have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ACTU. Download the app for real-time alerts.
- How can I analyze Actuate Therapeutics, Inc. Common stock stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.